Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Recruiting

Phase 1

Interleukin-15Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Sponsor:

Baylor College of Medicine

Code:

NCT04377932

Conditions

Liver Cancer

Rhabdomyosarcoma

Malignant Rhabdoid Tumor

Liposarcoma

Wilms Tumor

Eligibility Criteria

Sex: All

Age: 1 - 21

Healthy Volunteers: Not accepted

Interventions

AGAR T cells

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Baylor College of Medicine on 2025-04-17.